
Teva Pharmaceutical (TEVA) Stock Forecast & Price Target
Teva Pharmaceutical (TEVA) Analyst Ratings
Bulls say
Teva Pharmaceutical Indus is a dominant player in the pharmaceutical industry, with a strong presence in both the generic and innovative medicine markets. Its wide distribution network, global presence, and diversified portfolio make it a resilient company with strong potential for growth. Their focus on developing biosimilars and innovative treatments in neurology and immunology, coupled with their strategic investments in research and development, position them well for long-term success. The imminent release of top-line data for their anti-IL-15 drug candidate, along with their recent acquisition of Emalex Biosciences and their continued growth in key products, indicate a promising future for the company. However, risks such as regulatory changes and pricing uncertainty must be closely monitored in the pharmaceutical industry.
Bears say
Teva Pharmaceutical Indus is facing potential challenges in the future due to impending pricing changes for its innovative medicine Austedo, as well as competition from oral JAK inhibitors which have adverse side effects. Additionally, the Austedo franchise saw strong sales growth in 1Q26, but this was mostly due to inventory drawdown rather than actual volume growth. However, there is potential for continued growth in the neurology and immunology therapeutic areas, which could be a positive for the company's financials in the long term.
This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Teva Pharmaceutical (TEVA) Analyst Forecast & Price Prediction
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares